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OBJECTIVE: Available chemotherapy presents poor control over the development of metastatic melanoma.
FTY720 is a compound already approved by the Food and Drug Administration for the treatment of patients
with multiple sclerosis. It has also been observed that FTY720 inhibits tumor growth in vivo (experimental
models) and in vitro (animal and human tumor cells). The aim of this study was to evaluate the effects of
FTY720 on a metastatic melanoma model and in tumor cell lines.
METHODS: We analyzed FTY720 efficacy in vivo in a syngeneic murine metastatic melanoma model, in which
we injected tumor cells intravenously into C57BL/6 mice and then treated the mice orally with the compound
for 7 days. We also treated mice and human tumor cell lines with FTY720 in vitro, and cell viability and death
pathways were analyzed.
RESULTS: FTY720 treatment limited metastatic melanoma growth in vivo and promoted a dose-dependent
decrease in the viability of murine and human tumor cells in vitro. Melanoma cells treated with FTY720
exhibited characteristics of programmed cell death, reactive oxygen species generation, and increased b-
catenin expression. In addition, FTY720 treatment resulted in an immunomodulatory effect in vivo by
decreasing the percentage of Foxp3+ cells, without interfering with CD8+ T cells or lymphocyte-producing
interferon-gamma.
CONCLUSION: Further studies are needed using FTY720 as a monotherapy or in combined therapy, as different
types of cancer cells would require a variety of signaling pathways to be extinguished.
KEYWORDS: FTY720; Murine Melanoma B16F10; Apoptosis; Metastasis; Reactive Oxygen Species; b-Catenin;
Immunomodulation.
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& INTRODUCTION
FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-
diol; Fingolimod, Novartis) is a synthetic analogue of
myoricin, originally isolated from the extract of the fungus
Isaria sinclairii. The compound is a substrate for sphingosine
kinases (SphK1 and SphK2); its phosphorylated form,
FTY720-P, acts as an agonist of sphingosine 1-phosphate
(S1P) receptors (S1P1, S1P3, S1P4, S1P5), binding to them with
high affinity at sub-nano-molar concentrations (1). Several
groups have shown that FTY720 increases allograft survival
(2,3), promotes earlier recovery from ischemia and reperfu-
sion injury (4), and attenuates autoimmune diseases (5,6).
The mechanisms underlying the effects of FTY720 were first
described as the sequestration of lymphocytes in the thymus
and secondary lymphoid organs, thus preventing their
migration to inflammatory sites. However, other mechanisms
have been proposed for FTY720, such as immunomodulation.
Using experimental models of transplantation and autoim-
mune disease, our group demonstrated that FTY720 pre-
vented the increase in Th17 (T helper 17) cells, instead of
promoting Treg (T regulatory) expansion (3).
Another important effect of FTY720 has been observed in
tumor cells. The compound caused dose-dependent cell
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death in several human tumor cell lines, such as prostate
cancer (DU145), bladder cancer (T24, UMUC3, HT1197), and
hepatoma cells (HepG2, Huh-7, Hep3N) and a cisplatin-
resistant renal lineage (ACHN) (7-10). Several mechanisms
have been proposed to explain these antitumor effects,
which depend on the cell line analyzed. Wallington-Beddoe
et al. (11) reported that FTY720 induced autophagy in acute
lymphoblastic leukemia cells; this effect was not mediated
by the S1P1 receptor or by protein phosphatase 2a (PP2A)
activation. Liao et al. (12) demonstrated autophagy-induced
caspase 3-dependent apoptosis in U266 cells, a multiple
myeloma cell line. Azuma et al. (13) showed that FTY720
induced apoptosis in vitro and metastasis reduction in vivo
by inducing cytoskeletal changes and reduced integrin
expression in a syngeneic breast cancer model. FTY720
interaction with the S1P1 receptor in activated B cell-like
diffuse large B-cell lymphoma (ABC-DLBCL) blocked
STAT3 (Signal transducer and activator of transcription 3)
signaling and reduced lymphoma cell growth in vitro and in
vivo (14).
For this reason, FTY720 has been proposed as an enhancer
of the efficacy of anticancer therapies. Here, we show that
FTY720 is effective in vivo against the B16F10-Nex2 model of
syngeneic murine metastatic melanoma, and to better
understand the pathways associated with the antitumor
effects in our model, we evaluated the influence of the
compound on human and murine melanoma cell lines in
vitro.
& MATERIALS AND METHODS
In vivo evaluation of pulmonary metastasis
Male C57BL/6 mice, 6-8 weeks old, were purchased from
CEDEME-UNIFESP (Centro de Desenvolvimento de
Modelos Experimentais - UNIFESP). The guidelines in
"Principles of laboratory animal care" (NIH publication
No. 85-23, revised 1985) were followed, and all of the animal
experiments were performed using protocols approved by
the Ethics Committee for animal experimentation of Federal
University of Sa˜o Paulo, Brazil.
The animals were inoculated via the tail vein with 36105
viable B16F10-Nex2 melanoma cells. They were then treated
by gavage with 5 mg/kg/day of FTY720 (Novartis,
Switzerland) or 0.2 mL of PBS for 7 days, starting on the
same day of tumor cell inoculation. Eight days after the last
dose of the drug, the mice were anesthetized, their lungs
were harvested, and melanotic pulmonary nodules were
counted using a stereomicroscope.
Cells and culture conditions
B16F10, a syngeneic murine melanoma cell line in C57BL/
6 mice, was originally obtained from the Ludwig Institute
for Cancer Research, Sa˜o Paulo branch. B16F10-Nex2, a
subline isolated at the Experimental Oncology Unit (Federal
University of Sa˜o Paulo (UNIFESP), Paulista School of
Medicine, EPM-UNIFESP), retains the principal character-
istics of the original tumor cell line, namely, low immuno-
genicity and moderate virulence in vivo. It forms lethal
subcutaneous tumors without spontaneous metastasis,
which can be obtained by endovenous injection. Human
melanoma cell line A2058 was originally obtained from the
Memorial Sloan Kettering Cancer Center, New York.
Human cervical carcinoma (HeLa) cells were acquired from
Dr. Hugo P. Monteiro, Federal University of Sa˜o Paulo
(UNIFESP), Paulista School of Medicine. The MCF-7 human
breast carcinoma cell line was originally obtained from the
Ludwig Institute for Cancer Research. The cells were
cultivated in RPMI 1640 medium (pH 7.2; Gibco/Invitrogen,
Minneapolis, MN) supplemented with 10 mM HEPES (N-2-
hydroxyethylpiperazine-N-2-ethanesulfonic acid), 24 mM
sodium bicarbonate, and 10% fetal calf serum, all from
Gibco/Invitrogen, and 40 mg/mL of gentamycin (Hipolabor
Farmaceˆutica, Sabara´, MG, Brazil). The cells were maintained
in culture flasks at 37 C˚ in a humidified atmosphere with
5% CO2.
Cell viability assay
B16F10-Nex2 or human tumor cells were seeded in a 96-
well plate (103 cells/well/100 mL of complete medium) and
were treated 12 h later with increasing concentrations of
FTY720 (Novartis, Switzerland). Viable adherent cells were
counted after 24 or 48 h using Trypan blue dye. For some of
the experiments, the cells were previously incubated for 2 h
with 10 mM N-acetyl-L-cysteine or 15 mM L-cysteine (both
from Sigma-Aldrich, St. Louis, MO) and were then washed
with PBS and treated with FTY720 for 12 h. Alternatively,
B16F10-Nex2 cells were co-incubated with 12 mM FTY720
and 100 or 150 mM necrostatin-1 (Sigma-Aldrich) for 24 h.
Caspase-3 activity
The enzymatic activity of caspase-3 in B16F10-Nex2 cells
induced by FTY720 treatment was assayed using the
ApoTargetTM Caspase Colorimetric Protease Assay Kit
(Invitrogen, Carlsbad, CA), according to the manufacturer’s
instructions. Briefly, the cells were treated with 6 mM
FTY720 for 6 h and were then harvested and incubated
with chilled lysis buffer for 10 min in an ice bath. The lysate
was centrifuged at 10,000 g for 1 min, and the protein
concentration in the supernatant was measured using the
Bradford method. The extract was diluted to 4 mg/mL of
protein in lysis buffer, and 200 mg of the protein was
incubated with 50 mL of DTT-containing reaction buffer and
200 mM enzyme substrate (DEVD-pNA) at 37 C˚ for 2 h in a
96-well plate. The reaction was read at 400 nm in a
microplate reader (SpectraMax-M2 software).
Transmission electron microscopy
B16F10-Nex2 cells (56104) were cultivated on plastic disks
made from Aclar film, incubated with 12 mM FTY720 for
3 h, and then fixed in a mixture of 2.5% glutaraldehyde in
0.1 M sodium cacodylate buffer (pH 7.4) for 20 h. After
washing with sodium cacodylate buffer for 15 min, the cells
were fixed with 1% osmium tetroxide in sodium cacodylate
buffer for 2 h and were then incubated in an aqueous
solution of 0.4% uranyl acetate for 30 min. After each
treatment, the cells were washed with water for 10 min, and
reactions were run at room temperature. All of the reagents
were acquired from Sigma-Aldrich. The cells were dehy-
drated in graded ethanol solutions (70%, 95%, and 100%),
treated with propylene oxide twice for 15 min, embedded in
SPURR for 5 h at room temperature, and then embedded in
SPURR for 72 h at 70 C˚, with suitable regions carefully
selected for final trimming of the blocks. Ultra-thin sections
from the selected regions were collected on grids and were
stained in alcoholic 1% uranyl acetate and in lead citrate
prior to examination using a Jeol 100 CX Electron
Microscope (Tokyo, Japan).
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TUNEL assay
DNA fragmentation was analyzed by TUNEL assay (In
Situ Cell Death Detection kit, Roche Molecular Biochemicals,
Mannheim, Germany). Briefly, B16F10-Nex2 cells (16104)
were cultivated on round glass coverslips for 24 h at 37 C˚.
The cells were then treated with 6 mM FTY720 for 6 h,
washed with PBS, and fixed for 30 min at room temperature
with 2% formaldehyde (Sigma-Aldrich). After fixation, the
cells were washed with PBS and were permeabilized with
0.1% Triton X-100 (Sigma Aldrich) for 30 min; then, they
were washed again with PBS and incubated with TdT
(terminal deoxynucleotidyltransferase) in reaction buffer
with dUTP-fluorescein at 37 C˚ for 1 h. Finally, the cells were
washed and stained with 10 mg/mL of DAPI (Invitrogen) for
10 minutes. As a positive control, cells were incubated with
1 mg/mL of actinomycin D (Sigma-Aldrich) for 2 h. Images
were processed using ImageJ software (http://rsbweb.nih.
gov/ij/). The cells were analyzed using an Olympus BX-51
fluorescent microscope (Olympus, Center Valley, PA, USA).
Chromatin condensation analysis
B16F10-Nex2 cells (16104) were cultivated on round glass
coverslips for 24 h at 37 C˚ and were then treated with 6 mM
FTY720 for 4 h. The cells were washed with PBS and fixed
for 30 min at room temperature with 2% formaldehyde
(Sigma-Aldrich). After fixation, the cells were washed with
PBS and then incubated with 2 mM Hoechst 33342 dye
(Invitrogen) for 10 min. Images were processed with Image
J software. Fluorescent cells were analyzed using an
Olympus BX-51 microscope.
Superoxide anion production
The superoxide anion production was analyzed by
dihydroethidium (DHE) assay (Invitrogen). Briefly, B16F10-
Nex2 (16104) cells were cultivated on round glass coverslips
for 24 h and were treated with 6 mM FTY720 for 4 h. The
cells were then incubated with 5 mM DHE at 37 C˚ for
30 min. As a positive control, cells were incubated with
5 mM H2O2 (Sigma-Aldrich) for 20 min. Images were
processed with Image J software. Fluorescent cells were
analyzed using an Olympus BX-51 microscope.
Western blotting
B16F10-Nex2 cells (36107) were treated with 6 mM
FTY720 for 1 h. Cytoplasmic and nuclear extracts were
prepared using the Cellytic NuCLEAR Extraction Kit (Sigma-
Aldrich), according to the manufacturer’s instructions.
Briefly, the cells were pelleted and swollen with lysis buffer
for 15 min on ice. IGEPAL CA-630 was added to a final
concentration of 0.6%, and the mixture was immediately
centrifuged at 10,0006g for 30 sec. The supernatant at this
stage constituted the cytoplasmic extract. The pellet was
resuspended in extraction buffer and was then vortexed at
medium speed for 30 min and centrifuged at 20,0006g for
5 min. The supernatant at this stage constituted the nuclear
extract. The protein concentration was measured using the
Bradford method, and 40 mg of protein from each extract was
electrophoretically separated on a 10% SDS-PAGE gel and
was then transferred to a nitrocellulose membrane (Millipore,
Billerica, MA). The membranes were washed in washing
buffer (10 mM Tris-HCl, pH 8.0, 150 nM NaCl, and 0.05%
Tween 20, all from Sigma-Aldrich) and blocked with 5% skim
milk (Molico; Nestle, Sa˜o Paulo, Brazil) in washing buffer for
12 h at 4 C˚ with shaking. The membranes were then
incubated for 16 h at 4 C˚ with mouse monoclonal antibodies
(1:500) for the detection of murine b-catenin (Cell Signaling,
MA, USA). After 1 h of incubation with 1:1000 rabbit
anti-mouse peroxidase-conjugated antibody (Invitrogen),
immunoreactive proteins were detected with enhanced
chemiluminescence using an ECL detection system (GE
Healthcare).
Flow cytometry
The spleens were removed from C57BL/6 mice, and cell
suspensions were prepared by pressing the organs through
a 400-mm sterile nylon mesh. Single-cell suspensions were
placed in individual tubes and were incubated with lysis
buffer for 1 min to cause hemolysis. For surface markers,
16106 spleen cells were incubated for 20 min with rat anti-
mouse antibody (BD Biosciences Pharmingen), CD4PerCP,
CD3APC, and CD8PE. The cells were washed and fixed
with 4% paraformaldehyde in PBS for 20 min at room
temperature. For Foxp3 intracellular staining, 16106 spleen
cells were permeabilized with PBS containing 0.5 BSA and
0.1% saponin and were then incubated with anti-mouse
Foxp3FITC (eBioscience – San Diego, CA) for 30 min at
room temperature. The cells were washed with PBS
containing BSA and 0.2% saponin, fixed with 4% parafor-
maldehyde, and analyzed using flow cytometry.
IFN-c-producing cells were identified ex vivo using spleen
cells (16106) suspended in RPMI 1640 medium (Sigma-
Aldrich Brasil Ltda), ionomycin (1 mg/mL), and the protein
transport inhibitor brefeldin A (1 mg/ml) in a humidified
incubator containing 5% of CO2 at 37 C˚ for 4 h. The cells were
washed twice in ice-cold PBS (Sigma-Aldrich Brasil LTDA),
fixed overnight, and permeabilized with 0.2% Triton X-100
(6 min at 37 C˚). Then, the cells were washed twice in ice-cold
PBS and were pelleted and stained (30 min at 4 C˚) for
intracellular cytokines using anti-mouse IFN-c Alexa-Fluor
(eBioscience – San Diego, CA) flow cytometry analysis. The
cells were analyzed in a FACSCalibur Cell Cytometer using
Cell Quest Pro software (BD Biosciences). At least 10,000
events were evaluated.
Statistical analysis
Student’s two-tailed t-test was used for statistical analysis,
with p-values ,0.05 considered statistically significant.
& RESULTS
FTY720 reduces the development of metastatic
melanoma in vivo
Male C57BL/6 mice were injected i.v. with 36105 B16F10-
Nex2 melanoma cells. The mice were treated by gavage with
PBS (Control) or FTY720 (5 mg/kg/day) for 7 days, starting
on the day of tumor cell injection, and the number of lung
nodules was evaluated 8 days after the last dose of FTY720.
The median number of lung nodules in the FTY720-treated
group (125 nodules) decreased significantly when compared
to the control C57BL/6 mice (more than 300 nodules)
(Figure 1).
FTY720 has a cytotoxic effect on B16F10-Nex2
murine melanoma and human tumor cells in vitro
B16F10-Nex2 murine melanoma cells showed morpholo-
gical alterations and a reduction in the number of adherent
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cells after treatment with FTY720, as shown by light
microscopy in Figure 2A. When these cells were collected
with trypsin and were counted using a vital stain, a time-
and dose-dependent cytotoxic effect was observed on
B16F10-Nex2 cells (Figure 2B); additionally dose-dependent
cytotoxic effects were observed on A2058 human melanoma,
HeLa human uterine cervix carcinoma and MCF-7 human
breast carcinoma cells (Figure 2C) incubated with FTY720
for 24 h. A2058 melanoma was the most resistant cell line to
FTY720 treatment, followed by breast carcinoma MCF-7. All
of the tumor cells evaluated, except for A2058 melanoma,
showed IC50 values less than 10 mM.
FTY720 induces apoptosis in tumor cells
Next, we evaluated the cell death pathway induced by
FTY720 in B16F10-Nex2 murine melanoma cells.
After incubation with 6 mM FTY720 for 4 h, a significant
increase in tumor cells showing chromatin condensation
was observed after cell staining with Hoechst 33342. Forty
percent of FTY720-treated cells, but only 7% of control cells,
showed evident chromatin condensation (Figure 3A). By
transmission electron microscopy, important nuclear altera-
tions were also observed after the compound treatment,
mainly early chromatin aggregation (after 3 h) along with
complete nuclear membrane disruption (Figure 3B).
FTY720 treatment also induced strong DNA degradation
in B16F10-Nex2 cells detected by TUNEL assay. While 87%
of treated cells showed DNA degradation, only 2.5% of
control cells were positive on TUNEL assay (Figure 3C).
Strong activation of caspase-3, an important hallmark of
apoptosis, was observed in FTY720-treated cells (3D). The
addition of necrostatin, a necroptosis inhibitor (15), to the
cell culture before FTY720 treatment did not prevent
FTY720-induced death, indicating that necrosis is not
involved in the B16F10-Nex2 cell death pathway that is
induced by FTY720 (Figure 3E).
Accumulation of reactive oxygen species and
nuclear/cytoplasmic b-catenin in B16F10-Nex2 cells
after FTY720 treatment
Reactive oxygen species (ROS) are important regulators of
apoptosis (16). To evaluate the participation of ROS in
FTY720-induced cell death, intracellular anion superoxide
production was detected using DHE after short (4 h)
incubation with a low dose (6 mM) of FTY720. The
fluorescence intensity of cells treated with FTY720 was as
high as that of the positive control treated with 5 mM of
H2O2, with the majority of cells being positive in both
treatments, while untreated cells showed a few positive cells
with low fluorescence (Figure 4A). The role of ROS in
FTY720-induced apoptosis was confirmed by measuring cell
viability after pre-incubation of B16F10-Nex2 cells with the
ROS scavenger N-acetyl-l-cysteine (NAC) or L-cysteine,
following treatment with the compound. It was observed
that both antioxidants partially inhibited cell death in the
presence of FTY720 at the doses used (10 mM NAC and
15 mM L-cysteine) (Figures 4B-C). This result suggests that
ROS are among the apoptosis effector molecules induced by
FTY720.
Decreased expression of b-catenin has been reported in
advanced and metastatic prostate cancer, and Chua et al.
(17) reported that FTY720 restored b-catenin expression and
suppressed the growth of human prostate cancer xenografts
in nude mice. In agreement with this observation, B16F10-
Nex2 cells exhibited significantly increased expression of b-
catenin in their nuclei and cytoplasms after FTY720
treatment for 2 h compared to untreated cells, as observed
by immunoblotting (Figure 4D).
Immunomodulation by FTY720
To assess other possible roles played by FTY720 in the
melanoma model, we removed splenocytes from C57BL/6
mice 15 days after B16F10-Nex2 injections and investigated
ex vivo the percentages of T lymphocytes (CD4+ and CD8+),
Treg cells (CD4+Foxp3+), and IFN-producing lymphocytes
by flow cytometry. Mice treated with FTY720 evidenced a
significant decrease in the percentage of CD4+T cells,
whereas no significant change was observed for CD8+ T
cells (Figure 5A and 5C). Additionally, Treg cells decreased
in mice treated with FTY720, but no change was observed in
lymphocytes producing IFN-c (Figure 5B and 5D).
& DISCUSSION
Patients with advanced melanoma have a poor prognosis,
with 1-year survival rates as low as 33% and a median
overall survival (OS) of approximately 9 months (18).
Figure 1 - In vivo evaluation of pulmonary melanoma metastasis
after treatment with FTY720. A) C57BL/6 male mice were injected
i.v. with 36105 B16F10-Nex2 melanoma cells. The mice were
treated by gavage with PBS (Control) or with FTY720 (5 mg/kg/
day) for 7 days starting on the day of tumor cell inoculation, and
the number of metastatic nodules in the lungs was evaluated 8
days after the last dose of the compound (n=5 animals per
group). *p,0.04. B) Representative images of C57BL/6 mouse
lungs 15 days after melanoma cell inoculation.
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Systemic treatments are ineffective in general because
metastatic melanoma is largely refractory to the available
therapies. Dacarbazine (DTIC) remains the most commonly
used systemic agent, and when used alone or in combina-
tion with other agents, the response rates are less than 20%,
with an OS of less than 9 months (19). Interleukin-2 trials
reported durable complete responses in less than 10% of
patients, with significant toxicity (20).
FTY720 has been approved by the FDA for the treatment
of patients with refractory multiple sclerosis (21).
Additionally, this compound has been shown to exert
anti-cancer functions against chronic myelogenous leuke-
mia (22) and gastrointestinal tumors via activation of PP2A
(23) by unknown mechanisms.
Our results showed that FTY720 could limit B16F10-Nex2
metastatic melanoma development in vivo. Mice treated
with 5 mg/kg/day of FTY720 for 7 days, starting on the
same day as B16F10-Nex2 melanoma cell inoculation
evidenced a significant reduction in the number of meta-
static lung nodules when evaluated 15 days later. In
agreement with this finding, in a model of lung cancer
induction by a chemical carcinogen (urethane), it was
recently shown that FTY720 decreases tumor growth, which
is associated with reduced cell proliferation and VEGF
(endothelial growth factor) expression, in addition to
increased expression of activated caspase-3 (24).
LaMontagne et al. (25) reported a reduction in tumor cell
growth in vivo after the inoculation of B16/BL6 melanoma
cells in mouse ears and treatment with 3 mg/kg/day of
FTY720 for 14 days. Both the volumes and weights of
primary and cervical lymph node metastases were signifi-
cantly reduced after FTY720 treatment. In vitro, the
compound presented no cytotoxic or antiproliferative effects
on melanoma cells at a dose of 1000 nM (1 mM), and the
in vivo effects were attributed to the inhibition of tumor
angiogenesis. In agreement with this observation, we found
that 1 mM FTY720 had no effects on tumor cell apoptosis
after 24 h of culture. In contrast, 5 mM FTY720 caused a 20%
decrease in cell viability, whereas 8 mM FTY720 caused 70%
cell death in 24 h and complete extermination of cells in
48 h. A dose of 12 mM was able to eliminate all viable cells
after 24 h. Additionally, LaMontagne used B16/BL6 cells
possessing an aggressive metastatic capability, whereas we
evaluated B16F10-Nex2 cells, which presented moderate
virulence. In LaMontagne’s research, experimental cells
could not even be subjected to prolonged incubation
(.48 h) due to their rapid proliferative rate. Our results
showed that FTY720 inhibition of cancer development is
dose-dependent. For human therapy, FTY720 should be
used in higher doses or in combination with classic
chemotherapy, as human tumor cells likely possess more
aggressive metastatic capabilities.
Figure 2 - In vitro effects of FTY720 on murine melanoma and human tumor cell lines. A) B16F10-Nex2 morphological alterations, after
treatment with 1, 6, and 12 mM FTY720, were analyzed by light microscopy after 24 h. Control, untreated cells. Magnification, 40X. B)
Viable B16F10-Nex2 cells were counted after 24 or 48 h of treatment with increasing doses of FTY720. C) The A2058, HeLa, and MCF-7
human tumor cell lines were incubated with increasing doses of FTY720, and cell viability was evaluated after 24 h. Each experiment
was performed at least twice. The bars represent means and SDs.
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FTY720 also reduced the viability of a human melanoma
cell line (A2058) isolated from a metastatic lesion. After
24 h, a dose of 25 mM eliminated 90% of viable cells.
However, when compared to other human tumor lineages
(HeLa and MCF-7), the melanoma cell line was the most
resistant to the compound.
Next, we investigated the mechanism involved in FTY720-
mediated reduction of B16F10-Nex2 cell viability in vitro.
Several mechanisms have already been described for
FTY720 death induction in tumor cells, and this effect is
dependent on the tumor cell type.
Liao et al. (12) showed that FTY720 induced caspase-3-
dependent apoptosis in dose- and time-dependent manners
in U266 multiple myeloma cells by down-regulating the
antiapoptotic proteins Mcl-1, bcl-2, and survivin and the
cleavage of Bid. In these cells, apoptosis was preceded by
autophagy, as measured by the conversion of LC3-I into LC-
3II, a marker for autophagosome degradation.
In a lung tumor model, Saddoughi et al. (26) showed that
FTY720 interacts with the inhibitor (I2PP2A/SET) of the
tumor-suppressor enzyme PP2A, inducing RIPK1 (receptor-
interacting serine/threonine-protein kinase 1)-mediated
programmed necrosis (necroptosis) inhibited by necrostatin,
but apoptosis and autophagy were not involved in the cell
death process.
Our light microscopy results suggested that B16F10-Nex2
melanoma cells were not immediately lysed by FTY720
(Figure 2A), and electron microscopy did not reveal the
formation of cytoplasmic vacuoles after treatment (Figure 3B).
Together with caspase-3 activation, chromatin condensation
and DNA degradation, these results strongly suggest that
FTY720 treatment induced B16F10-Nex2 apoptosis and that
autophagy was not involved in the induction of apoptosis.
The addition of a necroptosis inhibitor (necrostatin-1) to the
cell culture before FTY720 treatment did not prevent the
death caused by the compound, indicating that necrosis is not
involved in the B16F10-Nex2 cell death pathway that is
induced by FTY720.
Some chemopreventive cancer agents induce apoptosis in
part through ROS generation and the disruption of redox
Figure 3 - FTY720 induces apoptosis in murine melanoma B16F10-Nex2. A) Murine melanoma cells were treated with 6 mM FTY720 for
4 h, and chromatin condensation was analyzed by fluorescence microscopy after DNA staining with Hoechst 33342. Arrows indicate
cells, shown in the images on the right side, with nuclear condensation apparent in FTY720-treated cells. B) Transmission electron
microscopy of B16F10-Nex2 cells after treatment with 12 mM FTY720 for 3 h. (a) Control and (b) FTY720. Squares indicate regions shown
in images on the right side. C)Melanoma cells were treated with 6 mM FTY720 for 6 h, and DNA degradation was observed with TUNEL
assay by fluorescent microscopy. Images of treated (right) and control (left) cells in phase contrast and after DAPI nuclear staining,
TUNEL staining, and merging of both images. D) In the same conditions described in (C), activation of caspase-3 by FTY720 in B16F10-
Nex2 cells was determined by colorimetric assay. E) B16F10-Nex2 cells were treated with 12 mM FTY720 for 24 h in the presence or
absence of 100 or 150 mM necrostatin-1. *p,0.04. Experiments A and C were performed at least 3 times, and the experiments
represented in B, D, and E were repeated twice. The bars represent means and SDs. Control, untreated cells.
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homeostasis (27). In addition to byproducts of mitochon-
drial respiration, ROS are also key signaling molecules that
regulate mitochondrial dysfunction and apoptotic events
(28). As secondary messengers, ROS can trigger the release
of pro-apoptotic proteins from the mitochondrial intermem-
brane space into the cytosol, such as cytochrome c, caspase-
9, apoptosis-inducing factor, and Smac/DIABLO (second
mitochondria-derived activator of caspases) (29), elevating
intracellular Ca2+ concentrations and activating the caspase
cascade (30). In acute lymphoblastic leukemia cells, the
inhibition of ROS production by 10 mM NAC treatment
prevented caspase-independent cell death (11).
Our results indicated that ROS are implicated in FTY720-
induced cell death. B16F10-Nex2 melanoma cells treated with
a low dose (6 mM) of FTY720 greatly increased their produc-
tion of superoxide anions, as analyzed by DHE staining. In
addition, the presence of the antioxidants NAC and L-cysteine
partially inhibited the cell death induced by FTY720, suggest-
ing that there are other regulating factors, in addition to ROS,
in the FTY720-induced cell death of B16F10-Nex2 cells.
Figure 4 - ROS production and b-catenin expression by B16F10-Nex2 cells after FTY720 treatment. A) B16F10Nex-2 cells were incubated
or not with 6 mM FTY720 for 4 h, and ROS production was determined by DHE assay and fluorescence microscopy. H2O2, positive
control treated with 5 mM hydrogen peroxide. B) B16F10Nex-2 cells were treated with 3.25-30 mM FTY720 after 2 h of pre-incubation
with 10 mM NAC or C) 15 mM FTY720 and pre-incubation with 15 mM L-cysteine, and cell viability was evaluated after 12 h. D)
Expression of b-catenin was analyzed by western blot of nuclear and cytoplasmic extracts of B16F10Nex-2 cells incubated with 6 mM
FTY720 for 1 h. *p,0.04.
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b-catenin is a key component of the Wnt/b-catenin
signaling pathway and a mediator of the Ras/phosphatidy-
linositol 3-kinase (PI3K) pathways (31). Active b-catenin
interacts with transcription factors, such as T cell factor/
lymphoid enhancer (TCF/LEF), CBP and p300, resulting in
target gene transcription, and it also binds to cadherins in the
cell membrane to provide structural support for adhesion
(32,33). The b-catenin pathway is well known as an enhancer
of proliferation and survival in tumor cells. However, its
overexpression or accumulation has also been reported to
induce apoptosis in several tumor cell lines. Raab et al. (34)
demonstrated that inhibition of PKC (protein kinase C)
resulted in the accumulation of active b-catenin, which
contributes to enzastaurin-induced cell death in multiple
myeloma cells. Overexpression of a stable form of b-catenin
or inhibition of endogenous b-catenin degradation has been
reported to lead to G2 cell cycle arrest and apoptosis in
epidermal keratinocytes (35). In malignant prostate cancer,
reduced expression of nuclear b-catenin was associated with
poorer prognosis (36), and restored functions of b-catenin
and E-cadherin were associated with decreased microvessel
density and VEGF expression in a mouse model of prostate
cancer (17). It has recently been shown that the activation of
Wnt/b-catenin signaling in vitro, in vivo (murine melanoma
model), or in patient tumors results in increased levels of
nuclear b-catenin, and this finding has been correlated with a
beneficial prognosis (37,38).
In our study, there was increased expression of b-catenin
in the nuclei and cytoplasms of B16F10-Nex2 cells treated
with FTY720, suggesting that this molecule could be
involved in the FTY720-induced cell death observed in
these murine melanoma cells.
In addition to the reduced development of metastatic
melanoma in vivo and increased melanoma cell death in
vitro caused by FTY720, our results ex vivo showed a
decrease in CD4+Foxp3+ cells in mice injected with B16F10-
Nex2 melanoma cells and treated with FTY720. Treg cells
have been shown to facilitate tumor development (39); thus,
FTY720 could act as an immunomodulator by decreasing
the numbers of these cells. Additionally, the capability of
lymphocytes to produce IFN-c was not changed by FTY720
treatment.
This study demonstrated that a low dose of orally
administered FTY720 was effective in limiting murine
metastatic melanoma development in vivo and that the
compound induced apoptosis in these tumor cells in vitro,
without indications of autophagy or necroptosis. Apoptotic
cell death was regulated by ROS and by increased
expression of b-catenin. FTY720 efficacy was obtained only
in higher doses when added in vitro to A2058 human
melanoma cells isolated from a metastatic lesion. In addition
to the cancer cell death induced by FTY720, we also
observed immunomodulation in the host immune system
Figure 5 - Ex vivo evaluation of C57BL/6 mouse spleen cells by flow cytometry, showing the percentages of CD4+T cells, CD4+Foxp3+
cells, CD8+ T cells, and lymphocytes producing IFN-c. Mice injected with B16F10Nex-2 cells and treated (FTY720) or not (Control) had
their spleens harvested 15 days later for the evaluation of A) CD4+ T cells, *p=0.0021; B) CD4+Foxp3+ cells; C) CD8+ T cells; D) IFN-c-
producing lymphocytes.
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caused by the compound, with a significant reduction in
Treg cell numbers.
It has already been shown that FTY720, administered in
association with chemotherapy, improves anticancer effects
mainly by inducing cell death (40). Further studies are
needed using FTY720 as a monotherapy or in combined
therapy, as different types of cancer cells could require the
involvement of a variety of signaling pathways to be
eliminated completely.
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